Site Navigation
General Information
Category: biotechnology & health
BSA 93-10: NHS-DOTA Synthesis
BNL Reference Number: BSA 93-10
Patent Status: U.S. Patent Number 5,428,156 was issued on June 27, 1995
Summary
NHS-DOTA
A route for synthesis of this N-hydroxysuccinimide ester compound is provided. The method introduces a single NHS-compound onto N, N', N'', N'''-Tetracyanomethylene-1,4,5,11-tetraazacyclotetradecane. The NHS-ester compound can be purchased commercially or may be made by licensed entities.
Description
This compound is a bifunctional chelating agent that is useful for tagging macromolecules or other biological compounds with metals, particularly radio-metals. The labeled biological compounds can then be used as tracers for labeling and detection with PET, and SPECT and may also be used for targeted therapy when linked to specific antibodies, for example.
Benefits
The methods are relatively straightforward for producing the NHS-DOTA compound.
Applications and Industries
Companies seeking methods for monitoring therapies and for administering therapeutic radiometals may find this simple compound useful.
Have Questions?
For more information about this technology, contact Christine Brakel, (631) 344-7134.
